171 related articles for article (PubMed ID: 37999147)
21. TCL-1-positive hematogones in a patient with T-cell prolymphocytic leukemia after therapy.
Hu Z; Li S; Medeiros LJ; Sun T
Hum Pathol; 2017 Jul; 65():175-179. PubMed ID: 28232160
[TBL] [Abstract][Full Text] [Related]
22. T-Cell Prolymphocytic Leukemia With t(X;14)(q28;q11.2): A Clinicopathologic Study of 15 Cases.
Hu Z; Medeiros LJ; Xu M; Yuan J; Peker D; Shao L; Tang Z; Mai B; Thakral B; Rios A; Hu S; Wang W
Am J Clin Pathol; 2023 Apr; 159(4):325-336. PubMed ID: 36883805
[TBL] [Abstract][Full Text] [Related]
23. Comparison of clinicopathological characteristics between T-cell prolymphocytic leukemia and peripheral T-cell lymphoma, not otherwise specified.
Kawamoto K; Miyoshi H; Yanagida E; Yoshida N; Kiyasu J; Kozai Y; Morikita T; Kato T; Suzushima H; Tamura S; Muta T; Kato K; Eto T; Seki R; Nagafuji K; Sone H; Takizawa J; Seto M; Ohshima K
Eur J Haematol; 2017 May; 98(5):459-466. PubMed ID: 28129454
[TBL] [Abstract][Full Text] [Related]
24. Consensus criteria for diagnosis, staging, and treatment response assessment of T-cell prolymphocytic leukemia.
Staber PB; Herling M; Bellido M; Jacobsen ED; Davids MS; Kadia TM; Shustov A; Tournilhac O; Bachy E; Zaja F; Porkka K; Hoermann G; Simonitsch-Klupp I; Haferlach C; Kubicek S; Mayerhoefer ME; Hopfinger G; Jaeger U; Dearden C
Blood; 2019 Oct; 134(14):1132-1143. PubMed ID: 31292114
[TBL] [Abstract][Full Text] [Related]
25. Fluorescent BAT-25 and BAT-26 analysis of T cell prolymphocytic leukaemia.
Bradshaw PS; Hamoudi R; Min T; Catovsky D; Houlston RS; Yuille MR
Leukemia; 1999 Dec; 13(12):2104-6. PubMed ID: 10602436
[TBL] [Abstract][Full Text] [Related]
26. [T-cell prolymphocytic leukemia: potential diagnostic pitfalls].
Dessart P; Lemaire P; Le Dû K; Sandrini J; Prophette B; Maillard H
Ann Dermatol Venereol; 2014 Dec; 141(12):777-81. PubMed ID: 25433931
[TBL] [Abstract][Full Text] [Related]
27. T-cell Prolymphocytic Leukemia.
Sud A; Dearden C
Hematol Oncol Clin North Am; 2017 Apr; 31(2):273-283. PubMed ID: 28340878
[TBL] [Abstract][Full Text] [Related]
28. Current understandings on T-cell prolymphocytic leukemia and its association with TCL1 proto-oncogene.
Sun S; Fang W
Biomed Pharmacother; 2020 Jun; 126():110107. PubMed ID: 32247279
[TBL] [Abstract][Full Text] [Related]
29. T-cell prolymphocytic leukemia.
Dearden CE
Clin Lymphoma Myeloma; 2009; 9 Suppl 3():S239-43. PubMed ID: 19778847
[TBL] [Abstract][Full Text] [Related]
30. From the archives of MD Anderson Cancer Center: Aleukemic T-prolymphocytic leukemia, a rare presentation and review of the literature.
Nahmod KA; Thakral B; Aakash FNU; Iyer SP; Medeiros LJ; Quesada AE
Ann Diagn Pathol; 2023 Feb; 62():152077. PubMed ID: 36549077
[TBL] [Abstract][Full Text] [Related]
31. [Successful Treatment of T-Cell Prolymphocytic Leukemia with Alemtuzumab].
Ueki D; Yoshida C; Tsutsumi Oota I; Seki M; Komeno T; Ito H; Ide Y
Gan To Kagaku Ryoho; 2019 May; 46(5):913-915. PubMed ID: 31189814
[TBL] [Abstract][Full Text] [Related]
32. Mutations in PIGA cause a CD52-/GPI-anchor-deficient phenotype complicating alemtuzumab treatment in T-cell prolymphocytic leukemia.
Johansson P; Klein-Hitpass L; Röth A; Möllmann M; Reinhardt HC; Dührsen U; Dürig J
Eur J Haematol; 2020 Dec; 105(6):786-796. PubMed ID: 32875608
[TBL] [Abstract][Full Text] [Related]
33. Cutaneous involvement by T-cell prolymphocytic leukemia presenting as livedoid vasculopathy.
Leckey BD; Kheterpal MK; Selim MA; Al-Rohil RN
J Cutan Pathol; 2021 Jul; 48(7):975-979. PubMed ID: 33837964
[TBL] [Abstract][Full Text] [Related]
34. A complex pattern of recurrent chromosomal losses and gains in T-cell prolymphocytic leukemia.
Soulier J; Pierron G; Vecchione D; Garand R; Brizard F; Sigaux F; Stern MH; Aurias A
Genes Chromosomes Cancer; 2001 Jul; 31(3):248-54. PubMed ID: 11391795
[TBL] [Abstract][Full Text] [Related]
35. An unusual case of T-cell prolymphocytic leukemia mimicking a cutaneous vasculitis.
Edmonds N; Guerra R; Noland MB; Schenck O; Krasner B; Gru AA
J Cutan Pathol; 2021 Oct; 48(10):1311-1316. PubMed ID: 34089197
[TBL] [Abstract][Full Text] [Related]
36. T-cell prolymphocytic leukemia: an aggressive T cell malignancy with frequent cutaneous tropism.
Magro CM; Morrison CD; Heerema N; Porcu P; Sroa N; Deng AC
J Am Acad Dermatol; 2006 Sep; 55(3):467-77. PubMed ID: 16908353
[TBL] [Abstract][Full Text] [Related]
37. [Research Advances of Genetics, Diagnosis and Treatment of T-cell Prolymphocytic Leukemia--Review].
Lai MF; Li F
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2021 Dec; 29(6):1977-1981. PubMed ID: 34893145
[TBL] [Abstract][Full Text] [Related]
38. Patterns of Late Relapse after Allogeneic Hematopoietic Stem Cell Transplantation in Patients with T-Cell Prolymphocytic Leukemia.
Shumilov E; Hasenkamp J; Szuszies CJ; Koch R; Wulf GG
Acta Haematol; 2021; 144(1):105-110. PubMed ID: 32259827
[TBL] [Abstract][Full Text] [Related]
39. T-cell prolymphocytic leukemia with a novel translocation (6;11)(q21;q23).
Wong KF; Chan JK; Sin VC
Cancer Genet Cytogenet; 1999 Jun; 111(2):149-51. PubMed ID: 10347553
[TBL] [Abstract][Full Text] [Related]
40. Combining epigenetic therapy with venetoclax overcomes alemtuzumab resistance in T-cell prolymphocytic leukemia. A case report of a 26-year-old man with a prior history of T-cell acute lymphoblastic leukemia and GI-T lymphoma.
Andersen MA; Valentin R; Dissing Sjö L; Borgwardt L; Schmiegelow K; Andersen MK; Marvig RL; Yde CW; Niemann CU
Acta Oncol; 2020 Dec; 59(12):1547-1551. PubMed ID: 32970500
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
